Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FFP versus Omniplasma in pediatric congenital heart surgery
2024-514073-22-01Phase 3Completed
- Sponsor
- Erasmus MC
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of octaplas lg and fresh-frozen plasma in Cardiovascular Malformation (CVM) and coagulation defects (2 arms), sponsored by Erasmus MC. Primary endpoint: Difference in postoperative coagulation variables. Started Sep 2024; status: completed.
02
Drugs
octaplas lgfresh-frozen plasma
03
Conditions
Cardiovascular Malformation (CVM)coagulation defects
Beyond the preview
Go deeper on 2024-514073-22-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514073-22-01.